24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic
hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the
efficacy of PEG-IFNα-2a + ribavirin administered for 24 or 48 weeks. It will be evaluated
whether 48 weeks of therapy may achieve better results compared to the standard duration (24
weeks).